Tobacco Documents Online

17/10 '96 13:44 FAX 41 38 32 77 76 Burson-MaY'steU.er ?-1-20 Biaom:r~~~n. W3v Landotj VVCt K 2PX TmlCphona: pi7t$Zt G2(ii Fac9ir.jh;: 017t.t3D 1033 i i 25th September 1996 Dtavid Greenberg Vice President Corporate Affairs Europe Piilitp Morris CAE Rue Joseph IL, 166 B-1000 Brussels Dear David At G L~, I+--t LI, An advanced biotech research organisation in the UK, Amersham Intetnational, is involved in the genome project -- the long term effort to jdentify aiI human genes- Through a friend of mine, I have discovered a possible Amersharn project that could have an impact on the tobacco industry. You may be miles ahead of me in this area, but I thought it Was important enough to pass aIong, just in case. The point of this project would be to help indilw%eduals understand their genetic susceptibility to disease related to smoking. Since we all react differently to the effects of smoldng, it obviously would be useful for each person to know whether or not he or she carries the genes that make ill effects likely. This work could be interesting to Philip Morris for at least three reasons: A simple test might eventually be devised to tell a smoker whether or not he is at risk. This would put the burden of any consequence from smolattg on the indivi.duai, and would clear the way for the non susceptible population to smoke with a clear conscience. • Philip Morris would be seen to be contributing to research into the health efFects of smoking. Among other things, the research could determine the proportion of the population most at rislS potentially a powerful piece of information. • Finally, someone will eventually get around to this Idnd of research. Wouldn't it be better to be leading it? aarc.nona • l~russct_. • 6udao-9-zt - Coorra.agi-,n • FranEfurt - ThC H..?ua • Hano u~ Londnn - t.ied r a r.7dsn • Mo:e•.nsro Oalo • Purig - I+r.iyLt.a • Rom-I • Stockttolrm • War73w .G:o whoU,-o.r+nq:1 offie4s tnroughout oSia •%.ue:ratia • Norlli ainWlca - Szutn 4.n•.ues S&T Neuchatel ---> CARCHMAN R- PM Q008/009 I andnn no. GDt529 Eq J•I, 4i)n.r 59 Y; +s;

17/10 '96 13:44 FAX 41 38 32 77 76 33urs on -Marsteller 2 David Greenberg 25th September 1996 S&T Neuchatel -+y-. CARC Aecording to my friend, pharaiaceutical companies are already investing massively in research into genetic association with certain diseases. As you may know, genes indicating susceptibility to breast cancer and prostate cancer already are identified. What is needed is more clinical studies to determine the relationship between gene structure and its clinical expression. As my friend puts it, we now need to triangulate three elements: the smoldng populatiott the gene structure, and the disease profile. I believe this is the area they would like to discuss. A few final words about Arnersham. Through its'US subsidiary, Arnersham owns the world's leading producer of gene sequencing chemicals (the product is Sequenase), and is a major research lab for biotechnology and nuclear medicine. Annual turnover is about $500 million. If you care to pursue this, I would be happy to dig deeper or get Manny together with the Arnersha.m people. I know they would welcome a chance to meet. With best regards MICSaEL JoHi.vsox Director of Media cc: M Bourlas